Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...

1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...